Your search for Spironolactone returned 6 results

The new packaging allows for ease of administration and convenience.

Patient with and without diabetes who received patiromer were more likely to remain on spironolactone at 12 weeks compared with those who received placebo, a subgroup analysis of the AMBER trial showed.

The risk for hyperkalemia was highest with use of steroidal MRAs in combination with other RAASi.

Evidence in favor of SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists for treating patients with diabetic kidney disease is growing.

Despite an increasing emphasis on HFmrEF over the past several years, there is a lack of authoritative guidance surrounding therapeutic approaches for these patients.

Investigators reviewed 13 trials of spironolactone and 1 trial of eplerenone.